CARLSBAD, Calif., Nov. 9, 2018 /PRNewswire/ -- Ionis
Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense
therapeutics, today announced that management will host an Investor
Day on Friday, December
7th at 7:30 a.m. Eastern
Time at Marriott East Side in New
York, NY.
The agenda for the meeting is as follows:
- 7:00 a.m. – 7:30 a.m. ET – Breakfast
- 7:30 a.m. – 12:30 p.m. ET – Presentations
- 12:30 p.m. – 1:00 p.m. ET – Networking luncheon
To register to attend the event, please visit the Investors
& Media page at www.ionispharma.com, enter your information and
select "Attending Live Event" from the dropdown menu.
A live audio webcast of the presentation will be available on
the Investors & Media section of the Company's website. A
replay of the presentation will be available on the website within
48 hours and will be archived for a limited time.
ABOUT IONIS PHARMACEUTICALS, INC.
As the leader in
RNA-targeted drug discovery and development, Ionis has created an
efficient, broadly applicable, proprietary antisense technology
platform with the potential to treat diseases where no other
therapeutic approaches have proven effective. Our drug discovery
platform has served as a springboard for actionable promise and
realized hope for patients with unmet needs – such as children and
adults with spinal muscular atrophy (SMA). We created
SPINRAZA® (nusinersen)* and are proud to have brought
new hope to the SMA community by developing the first and only
approved treatment for this disease.
Our sights are set on all the patients we have yet to reach with
a pipeline of more than 40 drugs with the potential to treat
patients with cardiovascular disease, rare diseases, neurological
diseases, infectious diseases and cancer. We created TEGSEDI™
(inotersen) the world's first RNA-targeted therapeutic approved for
the treatment of polyneuropathy of hereditary transthyretin (TTR)
amyloidosis (ATTR) in adult patients that our affiliate Akcea
Therapeutics is commercializing. Together with Akcea, we are also
bringing new medicines to patients with cardiometabolic lipid
disorders.
To learn more about Ionis follow us on twitter @ionispharma or
visit http://ir.ionispharma.com/.
*Spinraza is marketed by Biogen.
IONIS' FORWARD-LOOKING STATEMENT
This press release
includes forward-looking statements regarding Ionis' business, and
the therapeutic and commercial potential of SPINRAZA®,
TEGSEDI™ (inotersen), WAYLIVRA™ (volanesorsen) and Ionis'
technologies and products in development, including the business of
Akcea Therapeutics, Inc., Ionis' majority owned affiliate. Any
statement describing Ionis' goals, expectations, financial or other
projections, intentions or beliefs is a forward-looking statement
and should be considered an at-risk statement. Such statements are
subject to certain risks and uncertainties, particularly those
inherent in the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around
such drugs. Ionis' forward-looking statements also involve
assumptions that, if they never materialize or prove correct, could
cause its results to differ materially from those expressed or
implied by such forward-looking statements. Although Ionis'
forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors
currently known by Ionis. As a result, you are cautioned not to
rely on these forward-looking statements. These and other risks
concerning Ionis' programs are described in additional detail in
Ionis' annual report on Form 10-K for the year ended December 31, 2017, and most recent Form 10-Q
quarterly filing, which are on file with the SEC. Copies of these
and other documents are available from the Company.
In this press release, unless the context requires otherwise,
"Ionis," "Company," "we," "our," and "us" refers to Ionis
Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals™ is a trademark of Ionis
Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark
of Akcea Therapeutics, Inc. TEGSEDI™ is a trademark of
Akcea Therapeutics, Inc. WAYLIVRA™ is a trademark of
Akcea Therapeutics, Inc. SPINRAZA® is a registered
trademark of Biogen.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-host-investor-day-300747060.html
SOURCE Ionis Pharmaceuticals, Inc.